Chronic Idiopathic Constipation Market Research Forecast, Regional, Trends and Analysis to 2023

Market Highlights

The market in Asia Pacific is expected to grow rapidly in the coming years. By studying and analyzing the market, it shows that this region has a good growth potential due to increasing unhealthy eating habits and unhygienic conditions. The other major chronic disease found in this region is the gastric cancer.

Segmentation

The global chronic idiopathic constipation market is segmented on the basis of diagnosis, treatment, and end-user. On the basis of diagnosis, the market is segmented into blood tests, sigmoidoscopy, colonoscopy, balloon expulsion tests, anorectal manometry, colonic transit study, defecography, and others. On the basis of treatment, the market is segmented into drug and surgery. Drugs are further segmented into acid neutralizers, laxatives and antidiarrheal, antiemetics, antiulcer, lubiprostone (amitiza) and linaclotide (linzess), misoprostol (Cytotec), colchicine/probenecid (Col-Probenecid) and Onabotulinumtoxin A (also called botulinum toxin type A or Botox), and others. On the basis of end-user, the market is segmented into hospitals, gastroenterology clinics, diagnostic centers, and others.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/5931

Regional Analysis

The Americas dominates the global chronic idiopathic constipation market owing to the increasing prevalence of chronic constipation and the presence of a well-developed healthcare sector within the region. Moreover, the increasing healthcare expenditure and the presence of key players within regional boundaries provide a favorable background for the market growth.

Europe is the second largest in the global chronic idiopathic constipation market. Factors such as the increasing availability of funds for research and a huge patient population followed by a well-developed healthcare sector drive the market within the region.  

Asia Pacific is estimated to be the fastest growing market for chronic idiopathic constipation. This can be attributed to the presence of developing economies such as India and China and a huge patient population. Moreover, the increasing healthcare expenditure and a rapidly developing healthcare sector boost the market growth within the region.  

On the other hand, the Middle East and Africa has the least share in the global chronic idiopathic constipation market due to the low per capita healthcare expenditure and stringent government policies, especially within the African region. It is estimated that the Middle East holds a majority of the market within the Middle Eastern and African region. 

Access Report Details @  https://www.marketresearchfuture.com/reports/chronic-idiopathic-constipation-market-5931

Key Players

Some of the key players in this market are  Actavis (U.S.), Chugai Pharmaceutical (Japan), Ferring International Center S.A.(Switzerland), Synergy Pharmaceuticals (U.S.), Pfizer Inc (U.S.), GlaxoSmithKline (U.K.), Sanofi (France), Bayer (Germany), Salix Pharmaceuticals Ltd (U.S.), Sucampo Pharmaceuticals Inc (U.S.), Ironwood Pharmaceuticals (U.S.), Progenics Pharmaceuticals (U.S.), F. Hoffmann-La Roche AG (Switzerland), Boehringer Ingelheim GmbH (Germany), Daewoong Co. Ltd.(South Korea), Synergy Pharmaceuticals, Inc. (U.S.), and others

Benzodiazepines Market Size 2019 Growing Growth Opportunities, Driving Factors With Top Players

Market Highlights

Benzodiazepines (BZD) are a class of psychoactive drugs with sedative, hypnotic (sleep-inducing), anti-anxiety, anticonvulsant, and muscle relaxant properties. Benzodiazepines (BZD) are useful in treating anxiety, insomnia, agitation, seizures, muscle spasms and alcohol withdrawal.

The sale of Benzodiazepine has been declining due to their addictive side effects and the rise of alternate drugs such as selective serotonin reuptake inhibitors. However the last few years have witnessed a moderate rise in the sale of Benzodiazepines. The lack of efficacy and slow onset of action of selective serotonin reuptake inhibitors along with the fear of falling back on first generation anti-psychotic (barbiturate class) drugs have negated any market moves against Benzodiazepines. Development of short acting Benzodiazepines is an additional advantage in favour of barbiturates.

Some more restraints hampering the market growth are highly competitive and segmented market and a shift towards non-pharmacological therapies.

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/2281

Global Benzodiazepine market:

The Global Benzodiazepine market has been evaluated as a slowly growing market and it is expected that the market will reflect sluggish growth figures in future. The global Benzodiazepine market is expected to grow with CAGR of ~ 1.5% to 2.3 % during the forecast period.

The major participants of this market are: AstraZeneca plc, Eli Lilly and Company, GlaxoSmithKline plc, Pfizer, Inc., Sanofi S.A. and Merck & Co., Inc.

Regional Analysis:

Depending on geographic region, Benzodiazepine market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally developed countries led by North America is the largest market for Benzodiazepines. Europe is the second-largest market for Benzodiazepines. Asia pacific region is expected to be fastest growing region in Benzodiazepine market due to increasing spending on healthcare infrastructure.

Browse Complete Report: https://www.marketresearchfuture.com/reports/benzodiazepine-market-2281

Segmentation:

Global Benzodiazepines market has been segmented on the basis of application which comprises of disposable, reusable and others. On the basis of application; market is segmented into anxiety, insomnia, agitation, seizures, muscle spasms and alcohol withdrawal and as anaesthesia supplements. On the basis of time of action; market is segmented into long acting and short acting Benzodiazepines.

Barlow’s Syndrome Market Size Industry Insights, Top Trends, Drivers, Growth and Forecast to 2023

Market Highlights:

Barlow’s Syndrome is a condition in which there is an abnormality of the mitral valve of the heart. It is a condition in which the leaflets of the mitral valve swell into the left atrium of the heart as the valve closes during ventricular contraction. This abnormality prevents the valve from closing correctly, which causes it to leak.

The global Barlow’s Syndrome market is expected to grow at a CAGR of 9% during the forecast period.

Regional Analysis

The Americas dominate the global Barlow’s Syndrome market owing to the rising geriatric population, increasing genetic disorders, and increasing number of injuries leading to infections. The Americas are further segmented into North America and South America. North America holds the largest market is owing to increasing number of geriatric population, rising number of cardiovascular disorders, and growing population. Additionally, a rising number of market players launching newer products, technological advancements, and market players wanting to expand their foothold is likely to drive the growth of the Barlow’s Syndrome market in the North American region. For instance, according to the National Centre for Chronic Disease Prevention (CDC), in 2015 around 630,000 Americans died of cardiovascular disorders.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/5596

Europe accounts for the second largest market due to rising cardiovascular diseases, increasing funds and increasing healthcare expenditure. For instance, according to the Eurostat, Germany incurred healthcare expenditure over EUR 321 billion in 2014.  According to European Society of Cardiology (ESC), around Euro 196 billion was spend for CVD. Germany, France, and the U.K hold a significant share of the market due to increasing demand for technologically advanced devices and increasing awareness in terms of rare diseases, and rising overall growth of the medical device industry.

The Asia Pacific is the fastest growing Barlow’s Syndrome market across the globe, whose growth is attributed to the rising geriatric population, increasing prevalence cardiovascular diseases, and rapidly developing economies. For instance, according to ESCAPE (Economic and Social Commission for Asia and the Pacific), in the year 2016, approximately 12.4% of the population was 60 years and older, and is projected to increase to 1.3 billion people by 2050. Additionally, increasing healthcare expenditure and demand for new treatment options for rare diseases fuel the market growth. India and China are the major contributors to the market growth due to the rapid development of healthcare sector and increasing healthcare expenditure in these regions and increasing demand for diagnostic services.

On the other hand, the Middle East & Africa is expected to witness limited growth due to limited access to the healthcare resources and lack of awareness about rare diseases. In the Middle East, the growth of the market is driven by increasing availability of new diagnostic and treatment methods for various chronic diseases.

Access Report Details @ https://www.marketresearchfuture.com/reports/barlow-syndrome-market-5596

Segmentation

The global Barlow’s Syndrome market is segmented on the basis of type, treatment, diagnosis, and end-users.

On the basis of the type, the market is segmented as mitral valve stenosis, mitral valve prolapse, and mitral valve regurgitation.

On the basis of the treatment, the market is segmented into medications and surgery. Medications are further sub-segmented to beta-blockers and calcium blockers. The beta blockers further sub-segmented to atenolol and metoprolol. The calcium blockers are further sub-segmented into Verapamil and Diltiazem.   

On the basis of the diagnosis, the market is segmented into X-ray, electrocardiogram, and echocardiogram.

On the basis of the end user, the market is segmented into hospitals & surgical centers, research institutes, and specialty clinics.

Key Players

Some of the key players in the barlows syndrome market are Abbott, Medtronic, Edward Lifesciences Corporation, CryoLife, Inc., Boston Scientific Corporation, Micro Interventional Devices, Inc., Lepu Medical Technology Co., Ltd Neovasc, Inc., Sorin Group, TTK HealthCare, JenaValve Technology, Inc. among others.

Antidiuretic Drugs Market Research Forecast, Regional, Trends and Analysis to 2023

Market Highlights

The global antidiuretic drugs market is expected to show sharp growth over the forecast period. Increasing prevalence of diabetes and demand for new drugs for its treatment are the key factor for the market growth. Rising geriatric population with diabetes insipidus also drive the market growth. Also, use of antidiuretic drugs for the treatment of hypertension is found to be increasing across the globe.

The global antidiuretic drugs market is expected to grow at a CAGR of 9.7% during the forecast period and is estimated to reach USD 180 million by 2023.

Taste the market data and market information presented through more than 120 market data tables and figures spread over 200 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Antidiuretic drugs market research report–Global forecast till 2023.”

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/4306

Major Players in Antidiuretic drugs Market

Some of the key players in the global market are Par Sterile Products, LLC (U.S.), ADH Health (U.S.), Azevan Pharmaceuticals, Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Otsuka Holdings Co. Ltd (Japan), Taj Pharmaceuticals Limited (India) and ALLERGAN (U.S.).

Regional Analysis
The global antidiuretic drugs market consists of four regions: the Americas, Europe, Asia Pacific, and the Middle East & Africa.

The Americas dominate the global antidiuretic drugs market. It comprises of two regions namely North America and South America. The market in the American region is driven by the rising prevalence of diabetes insipidus. Increase in geriatric population with diabetes and hypertension also contribute to the market growth.

In Europe, increasing adoption of new drugs for the treatment of diabetes insipidus, and availability of funds for research and development.

Asia Pacific is the fastest growing and potential market for the antidiuretic drugs treatment, whose growth is attributed to the increase in the awareness about the use of antidiuretics for the treatment and its side effects. Expansion of healthcare system in developing countries in Asia Pacific also favors the market growth.

The Middle East & Africa is expected to witness steady growth due to rising demand for primary healthcare services.

Browse Report @ https://www.marketresearchfuture.com/reports/antidiuretic-drugs-market-4306

Segmentation
The global antidiuretic drugs market is segmented on the basis of types, which includes vasopressin, desmopressin, oxytocin, and others. Other types of antidiuretic drugs are argipressin, lypressin, ornipressin and terlipressin. On the basis of indication, the market is segmented into diabetes insipidus, hemophilia, hypertension, and others. Diabetes insipidus is further sub-segmented into central diabetes insipidus, nephrogenic diabetes insipidus, dipsogenic diabetes insipidus and gestational diabetes insipidus. Other indications are polyuria, polydipsia and enuresis. On the basis of end users, the market is segmented into hospitals, clinics, pharmaceutical companies, and others.

Obesity Treatment Market Size 2019 Growing Growth Opportunities, Driving Factors With Top Players

Market Scope

The Global Obesity Treatment market can expect to achieve an approximate CAGR of 16.7% during the forecast period (2017-2023), says Market Research Future (MRFR).

Market Boosters and Key Challenges

The world over, the high obesity rate has become a burden, and the dire need to bring it under control has risen as a result. World Health Organization (WHO) suggests that over 50% of the worldwide population is obese. Furthermore, in the year 2014, over 1.9 billion adults that were 18 years and above were overweight. Out of these, more than 600 million were reported obese. Obesity is connected to various chronic diseases, including hypertension, orthopedic disorders, diabetes, and cancer. In short, the accelerated expansion of the obese population is fueling the prevalence of chronic diseases. Consequently, the need for effective obesity treatment for curbing the growth of chronic diseases is on the rise.

At present, numerous solutions including exercise, diet, minimally invasive devices & implants, invasive surgeries, and drugs, are available to manage weight. Obesity refers to a multifactorial disease that involves a number of genetic as well as physiological factors contributing to disease progression. As the results of monotherapy are limited; a holistic approach to achieve effective obesity control has become necessary. Owing to this, a combination of drugs finds widespread use in the treatment of obesity. Successful clinical trials and the consequent emergence of advanced and innovative products like satiety drugs are projected to create growth opportunities for the market in the following years.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/5872

Gastric bypass procedure is considered the most popular bariatric surgery, followed by minimally invasive procedures. Shorter hospital stays, cost-effectiveness, and speedy recovery are few prominent factors elevating the demand for minimally invasive surgeries. Additionally, government initiatives with the aim of augmenting the adoption rate of minimally invasive surgeries to decrease the incidence of hospital-acquired infections, as well as hospital readmissions, will stimulate market growth as well.

Market Segmentation

The global market for obesity treatment can be segmented on the basis of type, diagnosis, treatment, and end-user.

With respect to the type, the market is considered for inactivity obesity, food obesity, anxiety obesity, venous obesity, atherogenic obesity, and gluten obesity.

Depending on the diagnosis, the market is categorized based on blood tests, physical examination, and others. The blood tests segment is further divided into cholesterol test, liver function test, thyroid test, and others. The physical examination segment caters to heart rate measurement, blood pressure measurement, and others.

Treatment-wise segments in the market are medication, surgery, lifestyle changes, and others. The medication segment can be broken down into orlistat, lorcaserin, phentermine and topiramate, liraglutide, and others. The surgery segment covers into gastric bypass surgery, Laparoscopic Adjustable Gastric Banding (LAGB), gastric sleeve, biliopancreatic diversion, gastric sleeve, and others.

The end-users covered by the report are hospitals, clinics, pharmacies, and others.

Browse Complete Report: https://www.marketresearchfuture.com/reports/obesity-treatment-market-5872

Regional Outlook

Middle East & Africa, Europe, America, and Asia Pacific are the key markets for obesity treatment.

The Americas is the leading obesity treatment market, with predictions of it retaining its position throughout the forecast period. The massive research and development (R&D) investments for the development of effective weight management solutions along with the commercial availability of minimally invasive procedures in the region favor market growth.

Bagging the second position in the global obesity treatment market, Europe benefits from the availability of funds for research, expanding obese population, and rising adoption of bariatric surgeries.

Developing at the fastest-rate, the Asia Pacific market is backed by the increasing awareness of adverse health effects associated with excess weight along with its impact amongst the regional population. Other beneficial factors include the growing disposable income, improving healthcare infrastructure, and the thriving medical tourism industry.

Lastly, Middle East and Africa is counted as the least profitable obesity treatment market. Poor economy and strict government policies, mostly in Africa, have a big hand in the abysmal performance of the overall market in the region.

Prominent Vendors

The prominent vendors competing in the worldwide obesity treatment market include Olympus Corporation (Japan), F. Hoffmann-La Roche, Ltd. (Switzerland), Cousin Biotech (France), VIVUS, Inc. (U.S.), Allergan (Republic of Ireland), Johnson & Johnson Services, Inc. (U.S.), Arena Pharmaceuticals, Inc. (U.S.), Orexigen Therapeutics, Inc. (U.S.), Medtronic (U.S.), USGI Medical, Inc. (U.S.), Covidien plc (Republic of Ireland), Mediflex Surgical Products (U.S.), EnteroMedics, Inc. (U.S.), Novo Nordisk A/S (Denmark), and others.

Gynecological Devices and Instruments Market Research Forecast, Regional, Trends and Analysis to 2023

Overview:

The detailed report of Market Research Future (MRFR) reveals that the global gynecological devices and instruments market is expected to achieve 7.4% CAGR during the forecast period (2018-2023). The gynecological devices and instruments are needed to provide better care to women during surgeries and other treatments.

The global gynecological devices and instruments market can easily ride on the investments made in the healthcare sector to the better structural situation of the service. At the same time, regulatory frameworks have become quite stringent which is driving the innovation forward.  Research funding, the massive patient pool of the Asia Pacific market, and increasing government initiatives are some of the major factors that can ensure substantial market growth during the forecast period.

However, the gynecological devices and instruments market could feel bottlenecked due to the rising cost of such treatments and lack of trained professionals. Poor economies are also expected to slow down market growth during the forecast period.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/5990

Segmental Analysis:

The global gynecological devices and instruments market, as discussed by MRFR in their recent report, is segmented by surgical devices, surgical instruments, application, and end-user.

Based on the surgical devices, the gynecological devices and instruments market is segmented into gynecological endoscopy devices, fluid management systems, endometrial ablation devices, and female sterilization/contraceptive devices. The gynecological endoscopy devices segment includes hysteroscope, colposcope, resectoscope, laparoscope, and endoscopic imaging systems. The endometrial ablation devices segment comprises balloon ablation devices, radiofrequency ablation devices, hydrothermal ablation devices, and others. The female sterilization/contraceptive devices segment consists permanent birth control and temporary birth control. The temporary birth control segment includes intravaginal rings, IUD, and subdermal contraceptive implants.

Based on the surgical instruments, the gynecological devices and instruments market consists scissors, forceps, needle holders, trocars, dilators, vaginal speculums, uterine depressors, uterine curettes, uterine sounds, and others. The forceps segment includes artery forceps, Allis forceps, and other forceps. The vaginal speculums segment comprises Cusco vaginal speculums, Pederson vaginal speculums, sim’s vaginal speculums, pediatric vaginal speculums, graves’ vaginal speculums, and others.

By application, the gynecological devices and instruments market is segmented into hysteroscopy, laparoscopy, colposcopy, dilation and curettage, endometrial ablation, endometrial biopsy, cervical cryosurgery, and others.

Based on the end-user, the gynecological devices and instruments market is segmented into ambulatory surgery centers, hospitals & clinics, research & academic institutes, and others. The hospitals & clinics segment is expected to rise substantially during the forecast period.

Browse Complete Report: https://www.marketresearchfuture.com/reports/gynecological-devices-instruments-market-5990

Regional Analysis:

MRFR in their report on the gynecological devices and instruments market includes the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

The Americas has the market lead, and it can be owed to the well-developed technology, high healthcare expenditure, and the presence of leading players. The region substantially spends in the development of the research and development sector due to which the regional market is getting involved in several product launches and other strategic moves.

Europe’s market depends mostly on the substantial expenditure in the research and development sector. Both governments and private organizations are contributing much in the development of the regional market which is now occupying the second spot.

The APAC market is basking in the prospect set by the revamped healthcare sector. Increasing demand for treatment and fast evolving expenditure dynamics. Government initiatives taken to create awareness regarding childbirth and motherhood in the region is also propelling investment in the region.

Competitive Landscape:

The global gynecological devices and instruments market, as reported by MRFR in their report, includes Boston Scientific Corporation (U.S.), B. Braun Melsungen AG (Germany), Ethicon, Inc. (U.S.), CooperSurgical Inc. (U.S.), Karl Storz GmbH & Co. KG (Germany), Hologic, Inc. (U.S.), Medtronic plc (U.S.), MedGyn Products (U.S.), Richard WOLF GmbH (Germany), Olympus Corporation (Japan), Stryker Corporation (U.S.), Sklar Surgical Instruments (U.S.), and others.

In 2019, an Israeli startup Diagnoz.me came up with a concept of a smartphone that can diagnose the presence of bacteria in the body. This would provide lab-grade results in minutes and save a substantial amount of money. The image-analysis software would require a disposable chip device as an add-on and can detect bacteria accurately. 

Clinical Alarm Management Market Size 2019 Growing Growth Opportunities, Driving Factors With Top Players

Market Synopsis

Market Research Future (MRFR) proposes that the global clinical alarm management market is slated to demonstrate 30.4% CAGR during the forecast period (2018-2023). Rising awareness regarding patient safety is highly favoring the market growth. Clinical alarms offer critical warnings to healthcare physicians or caretakers regarding a patient’s condition. Such devices are generally used in clinics and homes and hospitals. Clinical alarm management devices are developed using different non-invasive technology and software in order to monitor the condition of a patient. These solutions are extensively adopted by the ambulatory surgical centers and hospitals to respond to clinical alarms. They are implemented for some applications and include mobility solutions, clinical decision support tools, alarm auditing software, central monitoring systems, and clinical alarm reporting software.

Request For Sample Report: https://www.marketresearchfuture.com/sample_request/7510

Market Potential and Pitfalls

The clinical alarm is an essential solution for proper patient monitoring during critical conditions, the safety of the patients, and alert the healthcare staff regarding changes in a patient’s condition. Clinical alarm management is high in demand in clinics, hospitals, intensive care units, and healthcare facilities owing to the rising awareness regarding patient safety, increasing government mandates regarding the safety of the patients, and surging demand for best practices in healthcare centers and hospitals.

The market’s course is chiefly directed by the rising incidences of chronic diseases, need for cost-containment in the healthcare delivery, growth in the geriatric population, and increasing prominence of mHealth tools and big data.

On the contrary, sleep disruption caused due to noise, noise fatigue, and an unpleasant environment for the staff, patients, as well as families due to the noise of the alarm are some of the major concerns considered to vitiate the market growth throughout the appraisal period. Additionally, the unstandardized integrated alarm systems are likely to deter the market growth to a large extent.

Global Clinical Alarm Management Market: Segmental Analysis

The global clinical alarm management market has been segmented on the basis of component, product, and end-user.

By mode of product, the global clinical alarm management market has been segmented into physiological monitors, nurse call systems, bed alarms, EMR integration systems, mobility solutions, ventilators, clinical decision support tools, and central monitoring systems. Among these, the EMR integration systems segment is likely to occupy a significant share in the global market. The growth is credited to the burgeoning adoption of EHRs and interoperability solutions in the healthcare organizations, shift of POC diagnostics from hospitals to home care settings, rising healthcare reforms and regulatory requirements, and the need for integrated healthcare systems in order to improve the outcome and quality of healthcare systems.

By mode of component, the global clinical alarm management market has been segmented into services and solutions. Among these, the solutions segment is predicted to occupy a significant share. The growth is credited to the frequent need for improvements and upgrades in the software applications.

By mode of end-users, the global clinical alarm management market has been segmented into long-term care centers, hospitals, and ambulatory care centers & home care settings.

Browse Complete Report: https://www.marketresearchfuture.com/reports/clinical-alarm-management-market-7510

Regional Insights

Geographically, the clinical alarm management market span across regions namely, Europe, America, Asia-Pacific, and the Middle East and Africa.

Considering the global scenario, the American region is considered to dominate the global clinical alarm management market. Growing awareness regarding patient safety methods, increased healthcare infrastructure, and innovation by the healthcare companies are likely to influence the market. Moreover, awareness programs associated with clinical alarm management by organizations like the American Association of Critical-Care Nurses and Association for the Advancement of Medical Instrumentation are likely to add an impetus to the growth of the market.

Europe is predicted to occupy the second position due to the rising support from the government for the healthcare sector and surging awareness programs conducted by various foundations are estimated to contribute to the market growth. Factors like huge patient population and the increased number of hospitals in this region are highly influencing the market growth.

The Asia Pacific region is assumed to be the fastest growing region due to the presence of developing nations like China, India, and Australia. Moreover, with the increasing expenditure on healthcare by the government, innovation of latest technologies for instance launch of the mobile application in order to reduce noise in the hospitals, and development of software are some of the major factors contributing to the growth of the market in this region.

Industry Updates

February 11, 2019: A wholly owned subsidiary of Spok Holdings, Spok, Inc., will exhibit their latest evolution of integrated healthcare communication platform named Spok Care Connect. It comprises a clinical alarm and alerting management solution, a fully integrated healthcare contact center, and a multiple device application for the care team messaging.

Competitive Dashboard

The prominent players operating the global clinical alarm management market are Bernoulli Enterprise Inc., GE Healthcare, Medtronic, Ascom Holdings, Baxter, Mobile Heartbeat (Subsidiary of Hospital Corporation of America), Drager, Mindray Medical International, Capsule Technologie (Subsidiary of Qualcomm Life, Inc.), Vocera Communications, Connexall, Spok, Inc. (Subsidiary of Spok Holdings, Inc.), Masimo, and Koninklijke Philips N.V.